Treatment of burned rats with insulin-like growth factor I inhibits the catabolic response in skeletal muscle.
Thermal injury is associated with a pronounced catabolic response in skeletal muscle, reflecting inhibited protein synthesis and increased protein breakdown, in particular myofibrillar protein breakdown. Administration of insulin-like growth factor I (IGF-I) has a nitrogen-sparing effect after burn injury, but the influence of this treatment on protein turnover rates in skeletal muscle is not known. In the present study, we examined the effect of IGF-I on muscle protein synthesis and breakdown rates following burn injury in rats. After a 30% total body surface area burn injury or sham procedure, rats were treated with a continuous infusion of IGF-I (3. 5 or 7 mg . kg-1 . 24 h-1) for 24 h. Protein synthesis and breakdown rates were determined in incubated extensor digitorum longus muscles. Burn injury resulted in increased total and myofibrillar protein breakdown rates and reduced protein synthesis in muscle. The increase in protein breakdown rates was blocked by both doses of IGF-I and the burn-induced inhibition of muscle protein synthesis was partially reversed by the higher dose of the hormone. IGF-I did not influence muscle protein turnover rates in nonburned rats. The results suggest that the catabolic response to burn injury in skeletal muscle can be inhibited by IGF-I.
Department of Surgery, University of Cincinnati, and Shriners Hospital for Children, Cincinnati, Ohio 45267-0558, USA.
C H
CH
Fang
B G
BG
Li
J J
JJ
Wang
J E
JE
Fischer
P O
PO
Hasselgren
D000596:Amino Acids / Q000097:blood; D000818:Animals; D001830:Body Surface Area; D002056:Burns / Q000378:metabolism*; D006801:Humans; D007263:Infusions, Parenteral; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009124:Muscle Proteins / Q000096:biosynthesis / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012016:Reference Values; D014158:Transcription, Genetic; D014452:Ubiquitins / Q000096:biosynthesis / Q000235:genetics
D000596:Amino Acids; D009124:Muscle Proteins; D011994:Recombinant Proteins; D014452:Ubiquitins; D007334:Insulin-Like Growth Factor I